ATE464054T1 - Pharmazeutische zusammensetzung eines neuroaktiven steroids und anwendungen davon - Google Patents
Pharmazeutische zusammensetzung eines neuroaktiven steroids und anwendungen davonInfo
- Publication number
- ATE464054T1 ATE464054T1 AT06754274T AT06754274T ATE464054T1 AT E464054 T1 ATE464054 T1 AT E464054T1 AT 06754274 T AT06754274 T AT 06754274T AT 06754274 T AT06754274 T AT 06754274T AT E464054 T1 ATE464054 T1 AT E464054T1
- Authority
- AT
- Austria
- Prior art keywords
- pharmaceutical composition
- neuroactive steroid
- pregnan
- methoxymethyl
- imidazolyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003431 steroids Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68890505P | 2005-06-09 | 2005-06-09 | |
PCT/EP2006/005574 WO2006131392A1 (en) | 2005-06-09 | 2006-06-09 | Pharmaceutical compositions of a neuroactive steroid and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE464054T1 true ATE464054T1 (de) | 2010-04-15 |
Family
ID=36790861
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06754274T ATE464054T1 (de) | 2005-06-09 | 2006-06-09 | Pharmazeutische zusammensetzung eines neuroaktiven steroids und anwendungen davon |
AT10000305T ATE538797T1 (de) | 2005-06-09 | 2006-06-09 | Pharmazeutische zusammensetzungen mit neuroaktivem steroid und verwendungen davon |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT10000305T ATE538797T1 (de) | 2005-06-09 | 2006-06-09 | Pharmazeutische zusammensetzungen mit neuroaktivem steroid und verwendungen davon |
Country Status (26)
Country | Link |
---|---|
US (2) | US20090131383A1 (de) |
EP (3) | EP2168585B1 (de) |
JP (2) | JP2008542419A (de) |
KR (3) | KR20100095661A (de) |
CN (1) | CN101193640A (de) |
AT (2) | ATE464054T1 (de) |
AU (1) | AU2006256851C1 (de) |
BR (1) | BRPI0612921A2 (de) |
CA (1) | CA2611430C (de) |
CY (2) | CY1110199T1 (de) |
DE (1) | DE602006013622D1 (de) |
DK (2) | DK2168585T3 (de) |
EA (1) | EA013744B1 (de) |
ES (2) | ES2344313T3 (de) |
HK (2) | HK1118202A1 (de) |
HR (2) | HRP20100372T1 (de) |
IL (3) | IL187813A (de) |
NO (1) | NO20076319L (de) |
NZ (1) | NZ562979A (de) |
PL (2) | PL2168585T3 (de) |
PT (2) | PT2168585E (de) |
RS (2) | RS52199B (de) |
SI (2) | SI1888080T1 (de) |
UA (1) | UA94909C2 (de) |
WO (1) | WO2006131392A1 (de) |
ZA (1) | ZA200709188B (de) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2766380T (pt) | 2011-10-14 | 2019-07-29 | Sage Therapeutics Inc | Compostos de 19-nor pregnano 3,3-dissubstituídos, composições e seus usos |
WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
SI2986624T1 (sl) | 2013-04-17 | 2020-10-30 | Sage Therapeutics, Inc. | 19-nor nevroaktivni steroidi za metode zdravljenja |
WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
WO2014169833A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
EP3868382A1 (de) | 2013-07-19 | 2021-08-25 | Sage Therapeutics, Inc. | Neuroaktive steroide, zusammensetzungen und verwendungen davon |
HUE052308T2 (hu) | 2013-08-23 | 2021-04-28 | Sage Therapeutics Inc | Neuroaktív szteroidok, készítmények és alkalmazásuk |
US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
LT3206493T (lt) | 2014-10-16 | 2020-08-25 | Sage Therapeutics, Inc. | Kompozicijos ir būdai, skirti cns sutrikimams gydyti |
CN107404877A (zh) * | 2014-10-16 | 2017-11-28 | 萨奇治疗股份有限公司 | 靶向cns 障碍的组合物和方法 |
PL3224269T3 (pl) | 2014-11-27 | 2020-08-24 | Sage Therapeutics, Inc. | Kompozycje i sposoby leczenia zaburzeń OUN |
LT3250210T (lt) | 2015-01-26 | 2021-04-12 | Sage Therapeutics, Inc. | Kompozicijos ir būdai, skirti gydyti cns sutrikimus |
DK3258939T3 (da) | 2015-02-20 | 2022-12-12 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser heraf |
CN116162121A (zh) | 2016-07-11 | 2023-05-26 | 萨奇治疗股份有限公司 | C17、c20和c21取代的神经活性类固醇及其使用方法 |
CN111491637A (zh) * | 2017-09-07 | 2020-08-04 | 萨奇治疗股份有限公司 | 神经活性甾类及其使用方法 |
US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
BR112021011765A2 (pt) * | 2018-12-17 | 2021-08-31 | Intra-Cellular Therapies, Inc. | Compostos orgânicos |
AU2020231506A1 (en) * | 2019-03-04 | 2021-09-30 | Praxis Precision Medicines, Inc. | Methods for the treatment of perimenopause and menopause |
CR20210629A (es) | 2019-05-31 | 2022-03-22 | Sage Therapeutics Inc | Esteroides neuroactivos y composiciones de estos |
AU2020358002A1 (en) * | 2019-10-02 | 2022-04-21 | Praxis Precision Medicines, Inc. | Combinations of GABA-A receptor positive allosteric modulators and NMDA antagonists, NMDA negative allosteric modulators or NMDA partial agonists |
WO2021168106A1 (en) * | 2020-02-18 | 2021-08-26 | Praxis Precision Medicines, Inc. | Deuterated neurosteroid |
WO2022178000A1 (en) * | 2021-02-18 | 2022-08-25 | Praxis Precision Medicines, Inc. | Hemi-citrate salts of gaba-a positive allosteric modulator and crystalline form thereof |
WO2022177718A1 (en) | 2021-02-18 | 2022-08-25 | Sage Therapeutics, Inc. | Use of neuroactive steroid for treatment of sexual dysfunction |
CN117715641A (zh) * | 2021-04-26 | 2024-03-15 | 普拉西斯精密医药公司 | 用神经活性类固醇进行治疗的方法 |
WO2023159094A2 (en) * | 2022-02-16 | 2023-08-24 | Praxis Precision Medicines, Inc. | PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE |
WO2023159035A1 (en) | 2022-02-16 | 2023-08-24 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of cns-related disorders |
WO2023164386A1 (en) * | 2022-02-28 | 2023-08-31 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2535202B1 (fr) * | 1982-11-03 | 1985-08-09 | Fabre Sa Pierre | Comprimes de theophylline a liberation controlee et leur procede de fabrication |
US4861598A (en) * | 1986-07-18 | 1989-08-29 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
GB8626098D0 (en) | 1986-10-31 | 1986-12-03 | Euro Celtique Sa | Controlled release hydromorphone composition |
US4884909A (en) | 1986-12-25 | 1989-12-05 | Canon Kabushiki Kaisha | Recording apparatus |
US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
DE69535623T2 (de) * | 1994-02-14 | 2008-07-24 | Euro-Celtique S.A. | Androstane und Pregane zur allosterischen Modulation des GABA Rezeptors |
US5478572A (en) * | 1994-09-06 | 1995-12-26 | Bristol-Myers Squibb Co. | Gepirone dosage form |
US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
US7083808B2 (en) * | 1998-12-17 | 2006-08-01 | Euro-Celtique S.A. | Controlled/modified release oral methylphenidate formulations |
NZ515779A (en) * | 1999-04-29 | 2003-11-28 | Purdue Pharma Ltd | 3alpha-hydroxy-3beta methoxymethyl-21-heterocycle substituted steroids with anesthetic activity |
CO5210862A1 (es) * | 1999-09-15 | 2002-10-30 | Alza Corp | Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia |
US6080736A (en) * | 1999-10-27 | 2000-06-27 | Janus Pharmaceuticals, Inc. | Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam |
GB0218876D0 (en) * | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
US20060074059A1 (en) * | 2004-08-26 | 2006-04-06 | Goliber Philip A | Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one |
-
2006
- 2006-06-09 UA UAA200800334A patent/UA94909C2/ru unknown
- 2006-06-09 RS RS20120109A patent/RS52199B/en unknown
- 2006-06-09 KR KR1020107018375A patent/KR20100095661A/ko not_active Application Discontinuation
- 2006-06-09 JP JP2008515150A patent/JP2008542419A/ja active Pending
- 2006-06-09 NZ NZ562979A patent/NZ562979A/en not_active IP Right Cessation
- 2006-06-09 AU AU2006256851A patent/AU2006256851C1/en not_active Ceased
- 2006-06-09 EP EP10000305A patent/EP2168585B1/de active Active
- 2006-06-09 DE DE602006013622T patent/DE602006013622D1/de active Active
- 2006-06-09 WO PCT/EP2006/005574 patent/WO2006131392A1/en active Application Filing
- 2006-06-09 ES ES06754274T patent/ES2344313T3/es active Active
- 2006-06-09 CN CNA2006800200317A patent/CN101193640A/zh active Pending
- 2006-06-09 KR KR1020087000520A patent/KR20080017091A/ko active Search and Examination
- 2006-06-09 CA CA2611430A patent/CA2611430C/en not_active Expired - Fee Related
- 2006-06-09 RS RSP-2010/0265A patent/RS51304B/sr unknown
- 2006-06-09 SI SI200630698T patent/SI1888080T1/sl unknown
- 2006-06-09 EA EA200800007A patent/EA013744B1/ru not_active IP Right Cessation
- 2006-06-09 AT AT06754274T patent/ATE464054T1/de active
- 2006-06-09 BR BRPI0612921-8A patent/BRPI0612921A2/pt not_active IP Right Cessation
- 2006-06-09 ES ES10000305T patent/ES2380060T3/es active Active
- 2006-06-09 SI SI200631289T patent/SI2168585T1/sl unknown
- 2006-06-09 DK DK10000305.2T patent/DK2168585T3/da active
- 2006-06-09 EP EP06754274A patent/EP1888080B1/de active Active
- 2006-06-09 KR KR1020127005147A patent/KR20120028407A/ko not_active Application Discontinuation
- 2006-06-09 EP EP10010923A patent/EP2263675A3/de not_active Withdrawn
- 2006-06-09 PT PT10000305T patent/PT2168585E/pt unknown
- 2006-06-09 PL PL10000305T patent/PL2168585T3/pl unknown
- 2006-06-09 US US11/921,889 patent/US20090131383A1/en not_active Abandoned
- 2006-06-09 DK DK06754274.6T patent/DK1888080T3/da active
- 2006-06-09 PT PT06754274T patent/PT1888080E/pt unknown
- 2006-06-09 PL PL06754274T patent/PL1888080T3/pl unknown
- 2006-06-09 AT AT10000305T patent/ATE538797T1/de active
-
2007
- 2007-10-25 ZA ZA200709188A patent/ZA200709188B/xx unknown
- 2007-12-02 IL IL187813A patent/IL187813A/en not_active IP Right Cessation
- 2007-12-07 NO NO20076319A patent/NO20076319L/no not_active Application Discontinuation
-
2008
- 2008-08-18 HK HK08109178.7A patent/HK1118202A1/xx not_active IP Right Cessation
- 2008-08-18 HK HK10107380.1A patent/HK1140947A1/xx not_active IP Right Cessation
-
2010
- 2010-07-02 HR HR20100372T patent/HRP20100372T1/hr unknown
- 2010-07-09 CY CY20101100642T patent/CY1110199T1/el unknown
-
2011
- 2011-02-08 IL IL211114A patent/IL211114A/en not_active IP Right Cessation
- 2011-11-07 IL IL216194A patent/IL216194A/en not_active IP Right Cessation
-
2012
- 2012-03-21 CY CY20121100298T patent/CY1112499T1/el unknown
- 2012-03-23 HR HR20120264T patent/HRP20120264T1/hr unknown
- 2012-05-04 US US13/464,369 patent/US20120276196A1/en not_active Abandoned
- 2012-07-23 JP JP2012162303A patent/JP2012229261A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE464054T1 (de) | Pharmazeutische zusammensetzung eines neuroaktiven steroids und anwendungen davon | |
BRPI0708038B8 (pt) | derivado de cumarina, composição farmacêutica e agente terapêutico para um distúrbio proliferativo celular | |
GEP20115143B (en) | Combination of azelastine and fluticasone | |
PT2038290E (pt) | Moduladores de receptor do tipo toll 7 | |
NO20092723L (no) | Indazolylester og amidderivater for behandling av gluccocorticoid reseptormedierte sykdommer | |
BRPI0517891A (pt) | composições compreendendo azelastina e métodos de uso das mesmas | |
CO5140098A1 (es) | Combinaciones de un agonista de betra-2 y un esteroide, su uso para tratamiento de enfermedades inflamatorias u obstructivas de las vias aereas | |
GEP20115213B (en) | Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists | |
FR2909284B1 (fr) | Nouvelles compositions sous forme d'onguent sans vaseline comprenant un derive de vitamine d et eventuellement un anti-inflammatoire steroidien | |
WO2008010921A3 (en) | Modulators of pharmacokinetic properties of therapeutics | |
BRPI0607523A2 (pt) | compostos esteróides de heteroarila c-17, composições farmacêuticas compreendendo os mesmos e uso dos referidos compostos na preparação de medicamentos | |
WO2006044362A3 (en) | N-sulfonylpiperidine cannabinoid receptor 1 antagonists | |
AU2003207016A1 (en) | Pharmaceutical formulation for administration by inhalation comprising an androstane derivative and a beta-2-adrenoreceptor for the treatment of inflammatory and allergic conditions | |
EP2425874A3 (de) | Verwendung von einer Vitamin D Verbindung und eines zusätzlichen therapeutischen Mittel in der Behandlung von Krebs | |
EA200901393A1 (ru) | Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат | |
BRPI0515103A (pt) | composição farmacêutica, inalador, processos para preparar o mesmo, e uma composição farmacêutica, e, uso de uma composição farmacêutica | |
WO2008012338A3 (en) | Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions | |
WO2006036981A3 (en) | Small molecule modulators of cytokine activity | |
SE0400346D0 (sv) | Steroids for cancer treatment | |
BRPI0618370A2 (pt) | formulação aerossol de medicamento, uso do mesmo e kit de inalação | |
NO20065657L (no) | Filmformet ostriol-inneholdende medikament for oral administrasjon | |
CL2007001894A1 (es) | Formulacion oftalmica topica que comprende: 0,1% de dexametasona, 0,3% de clorhidrato de ciprofloxacino, cloruro de sodio, 6% de hidroxipropil-beta-ciclodextrina, 0,15% de sulfato de sodio, 0,05% de edetato disodico, 0,022% de cloruro de benzalconio al 50% y 0,100ml/100ml de polisorbato 80; util para tratar infecciones oculares. | |
BR122014030158B8 (pt) | formulação farmacêutica | |
WO2007063428A3 (en) | Pharmaceutical compositions comprising carboxyalkylsulfonic acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1888080 Country of ref document: EP |